Quick off the mark30 Nov 2021 07:18
BATM confirms effectiveness of its COVID-19 RT-PCR tests in diagnosing Omicron strain
BVC RNS
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that its COVID-19 RT-PCR kits have been validated as effective against the new SARS-CoV-2 variant, Omicron, and confirms that they can accurately diagnose COVID-19 in someone with this new strain.